Complications of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Systematic Literature Review.

IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY
Gunjan Jindal, Yekta Sharafaddin-Zadeh, Omar Bukhari, Mayank Goyal, Johanna M Ospel
{"title":"Complications of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Systematic Literature Review.","authors":"Gunjan Jindal, Yekta Sharafaddin-Zadeh, Omar Bukhari, Mayank Goyal, Johanna M Ospel","doi":"10.1017/cjn.2025.10369","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic subdural hematoma (cSDH) is a common condition, especially in the older population, and causes considerable morbidity. Recently, middle meningeal artery embolization (MMAE) has shown promise as a minimally invasive intervention for cSDH by disrupting the flow to the hematoma neomembranes and thus reducing recurrence.</p><p><strong>Methods: </strong>We performed a systematic review of the literature using PubMed/Medline and Google Scholar to identify studies reporting on MMAE for cSDH over the past 30 years. After screening 4103 articles and reviewing 600 full-text studies, 176 studies were selected, including case reports, case series, retrospective and prospective studies and randomized controlled trials. Patient demographics, embolic agents used, frequency, type and severity of complications, hematoma recurrence and need for repeat surgery were extracted from the included studies.</p><p><strong>Results: </strong>Our analysis included 9780 patients (75.9% male), with mean/median ages ranging from 62.1 to 82.5 years. MMAE-related complications were reported in approximately 3%. Procedure-related neurological complications were the most frequent, followed by systemic complications, access site, non-procedure-related neurological complications, procedure-linked vascular complications specific to MMA and miscellaneous complications. Hematoma recurrence was reported in 6%, and repeat or rescue surgery was necessary in 6.1%. These results are consistent with major clinical trials evaluating MMAE safety and efficacy in cSDH.</p><p><strong>Conclusion: </strong>Based on current published literature, MMAE appears to be an effective and overall safe treatment option for cSDH. Complications, although infrequent, can occur, and some of these are disabling. Meticulous pre-procedural planning and imaging are essential to reduce the risk of complications.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/cjn.2025.10369","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic subdural hematoma (cSDH) is a common condition, especially in the older population, and causes considerable morbidity. Recently, middle meningeal artery embolization (MMAE) has shown promise as a minimally invasive intervention for cSDH by disrupting the flow to the hematoma neomembranes and thus reducing recurrence.

Methods: We performed a systematic review of the literature using PubMed/Medline and Google Scholar to identify studies reporting on MMAE for cSDH over the past 30 years. After screening 4103 articles and reviewing 600 full-text studies, 176 studies were selected, including case reports, case series, retrospective and prospective studies and randomized controlled trials. Patient demographics, embolic agents used, frequency, type and severity of complications, hematoma recurrence and need for repeat surgery were extracted from the included studies.

Results: Our analysis included 9780 patients (75.9% male), with mean/median ages ranging from 62.1 to 82.5 years. MMAE-related complications were reported in approximately 3%. Procedure-related neurological complications were the most frequent, followed by systemic complications, access site, non-procedure-related neurological complications, procedure-linked vascular complications specific to MMA and miscellaneous complications. Hematoma recurrence was reported in 6%, and repeat or rescue surgery was necessary in 6.1%. These results are consistent with major clinical trials evaluating MMAE safety and efficacy in cSDH.

Conclusion: Based on current published literature, MMAE appears to be an effective and overall safe treatment option for cSDH. Complications, although infrequent, can occur, and some of these are disabling. Meticulous pre-procedural planning and imaging are essential to reduce the risk of complications.

脑膜中动脉栓塞治疗慢性硬膜下血肿的并发症:系统的文献回顾。
背景:慢性硬膜下血肿(cSDH)是一种常见的疾病,特别是在老年人群中,引起相当大的发病率。最近,脑膜中动脉栓塞术(MMAE)通过破坏血肿新膜的血流从而减少复发,显示出了作为cSDH微创干预的希望。方法:我们使用PubMed/Medline和谷歌Scholar对文献进行系统回顾,以确定过去30年关于MMAE治疗cSDH的研究报告。在筛选了4103篇文章和600篇全文研究后,选择了176项研究,包括病例报告、病例系列、回顾性和前瞻性研究以及随机对照试验。从纳入的研究中提取患者人口统计资料、使用的栓塞剂、并发症的频率、类型和严重程度、血肿复发和需要重复手术。结果:我们的分析包括9780例患者(75.9%为男性),平均/中位年龄为62.1至82.5岁。mmae相关并发症约占3%。手术相关的神经系统并发症是最常见的,其次是全身并发症、通路部位、非手术相关的神经系统并发症、MMA特异性的手术相关血管并发症和其他并发症。血肿复发占6%,再次或抢救手术占6.1%。这些结果与评估MMAE在cSDH中的安全性和有效性的主要临床试验一致。结论:根据目前发表的文献,MMAE似乎是cSDH的一种有效且总体安全的治疗选择。并发症,虽然不常见,但可能发生,其中一些是致残的。细致的术前计划和影像学检查对于减少并发症的风险至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
3.30%
发文量
330
审稿时长
4-8 weeks
期刊介绍: Canadian Neurological Sciences Federation The Canadian Journal of Neurological Sciences is the official publication of the four member societies of the Canadian Neurological Sciences Federation -- Canadian Neurological Society (CNS), Canadian Association of Child Neurology (CACN), Canadian Neurosurgical Society (CNSS), Canadian Society of Clinical Neurophysiologists (CSCN). The Journal is a widely circulated internationally recognized medical journal that publishes peer-reviewed articles. The Journal is published in January, March, May, July, September, and November in an online only format. The first Canadian Journal of Neurological Sciences (the Journal) was published in 1974 in Winnipeg. In 1981, the Journal became the official publication of the member societies of the CNSF.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信